drugset / Trial / NCT00546728
The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes
Phase 4
Completed
50 enrolled
St. Paul Heart Clinic
Amylin Pharmaceuticals, LLC. · collabEli Lilly and Company · collabInternational Diabetes Center at Park Nicollet · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the effects of exenatide versus metformin on vascular health with chronic (3-month) therapy and during a 2-hour period following a meal in patients with pre-diabetes. It is predicted that exenatide will improve vascular health to a greater degree compared to metformin.
Timeline
- Start
- 2007-10
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 10 ug | — |
| Comparator | Metformin | Small molecule | 500 mg | — |